These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26373914)

  • 1. [What happens after discontinuation of anticoagulation after unprovoked pulmonary embolism?].
    Praxis (Bern 1994); 2015 Sep; 104(19):1043-4. PubMed ID: 26373914
    [No Abstract]   [Full Text] [Related]  

  • 2. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
    Couturaud F; Sanchez O; Pernod G; Mismetti P; Jego P; Duhamel E; Provost K; dit Sollier CB; Presles E; Castellant P; Parent F; Salaun PY; Bressollette L; Nonent M; Lorillon P; Girard P; Lacut K; Guégan M; Bosson JL; Laporte S; Leroyer C; Décousus H; Meyer G; Mottier D;
    JAMA; 2015 Jul; 314(1):31-40. PubMed ID: 26151264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation therapy: Benefits of extended oral anticoagulation after first episode of pulmonary embolism.
    Huynh K
    Nat Rev Cardiol; 2015 Sep; 12(9):499. PubMed ID: 26216623
    [No Abstract]   [Full Text] [Related]  

  • 4. ACP Journal Club: after treating unprovoked PE with VKAs for 6 months, warfarin for 18 more months reduced a composite of VTE or major bleeding.
    Lipchik RJ
    Ann Intern Med; 2015 Nov; 163(10):JC6. PubMed ID: 26571260
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombophilia and the Risk of Recurrent Venous Thromboembolism.
    Rhinehart ZJ; Rivera-Lebron B; George MP
    JAMA; 2015 Nov; 314(18):1975-6. PubMed ID: 26547471
    [No Abstract]   [Full Text] [Related]  

  • 6. Thrombophilia and the Risk of Recurrent Venous Thromboembolism--Reply.
    Couturaud F; Meyer G; Mottier D
    JAMA; 2015 Nov; 314(18):1976. PubMed ID: 26547473
    [No Abstract]   [Full Text] [Related]  

  • 7. [Coronary heart disease: Genetic score identifies risk patients].
    Konstantinides S
    Dtsch Med Wochenschr; 2015 Sep; 140(19):1418. PubMed ID: 26402173
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment Trends for Prostate Cancer--Reply.
    Cooperberg MR; Carroll PR
    JAMA; 2015 Nov; 314(18):1977-8. PubMed ID: 26547474
    [No Abstract]   [Full Text] [Related]  

  • 9. Warfarin Discontinuation in Patients With Unprovoked Venous Thromboembolism: A Large US Insurance Database Analysis.
    Xie L; Liu X; Phatak H; Mardekian J; Tan W; Baser O; Ramacciotti E
    Am J Ther; 2016; 23(6):e1744-e1753. PubMed ID: 26214203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism.
    Bauer KA
    JAMA; 2011 Apr; 305(13):1336-45. PubMed ID: 21386068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.
    Nordstrom BL; Evans MA; Murphy BR; Nutescu EA; Schein JR; Bookhart BK
    Curr Med Res Opin; 2015 Mar; 31(3):439-47. PubMed ID: 25495136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes.
    Kearon C
    J Thromb Haemost; 2007 Dec; 5(12):2330-5. PubMed ID: 18034763
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute pulmonary embolism.
    Naina HV; Quevedo FJ
    N Engl J Med; 2008 Jun; 358(25):2745; author reply 2745-6. PubMed ID: 18572456
    [No Abstract]   [Full Text] [Related]  

  • 15. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
    Farraj RS
    Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants.
    Prandoni P; Milan M; Sarolo L; Zanon E; Bilora F
    Int Angiol; 2017 Oct; 36(5):395-401. PubMed ID: 27982558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-dimer testing to determine the duration of anticoagulation therapy.
    Palareti G; Cosmi B; Legnani C; Tosetto A; Brusi C; Iorio A; Pengo V; Ghirarduzzi A; Pattacini C; Testa S; Lensing AW; Tripodi A;
    N Engl J Med; 2006 Oct; 355(17):1780-9. PubMed ID: 17065639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
    Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
    J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic Therapies in Anticoagulation.
    Ferreira JL; Wipf JE
    Med Clin North Am; 2016 Jul; 100(4):695-718. PubMed ID: 27235611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of early anticoagulant therapy for venous thromboembolism in polytrauma patients in the acute phase.
    Nakagawa Y; Inokuchi S; Tsuji T; Yamagiwa T; Iizuka S; Morita S; Ootsuka H; Akieda K
    Tokai J Exp Clin Med; 2012 Dec; 37(4):121-5. PubMed ID: 23238904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.